T.ChenJ
To stay ahead of this shifting environment, pharma companies should consider the following imperatives: Massive patient drop-off undermines obesity GLP-1 uptake: Despite strong demand, only 10% of obesity patients persist with therapy after one year
Ekta Gupta, chief of gastroenterology at the University of Maryland Medical Center, explains that GLP-1 medications (also known as GLP-1 agonists) mimic hormones that help regulate blood sugar and appetite
Gastrointestinal effects GI side effects dominate the adverse event profile, consistent with all GLP-1 receptor agonists
Yang Y, Cui X, Chen Y, Wang Y, Li X, Lin L et al (2014) Exendin-4, an analogue of glucagon-like peptide-1, attenuates hyperalgesia through serotonergic pathways in rats with neonatal colonic sensitivity